Key Differences Between Old and New Guidelines for ANCA-Associated Kidney Vasculitis
The most transformative changes from the 2016 EULAR/ERA-EDTA guidelines to the 2024 KDIGO guidelines center on dramatically reduced glucocorticoid dosing, the introduction of avacopan as a steroid-sparing agent, more restrictive use of plasma exchange, and extended maintenance therapy duration based on relapse risk stratification.
Major Therapeutic Shifts
1. Glucocorticoid Dosing: Radical Reduction
The 2024 KDIGO guidelines 1 implement the reduced-dose PEXIVAS regimen, which represents a fundamental departure from older protocols:
- Week 1 dosing: 50-75 mg (weight-based) versus traditional high-dose protocols
- Rapid taper: Down to 5 mg by week 16-20, maintained at 5 mg through week 52
- Critical difference: This is approximately 50% less cumulative steroid exposure than older guidelines
The 2016 EULAR guidelines 2 did not specify such aggressive steroid reduction, representing a major quality-of-life improvement given steroid toxicity is a primary driver of morbidity.
2. Avacopan: New Steroid-Sparing Option
The 2024 guidelines introduce avacopan (C5a receptor antagonist) as an alternative to glucocorticoids 1:
- Dosing: 30 mg twice daily in combination with rituximab or cyclophosphamide
- Target population: Patients at high risk of glucocorticoid toxicity or with lower GFR (who may benefit from greater GFR recovery)
- Duration: Used throughout the 52-week induction/early maintenance period
This option was completely absent from 2016 guidelines 2, representing a paradigm shift toward complement-targeted therapy.
3. Plasma Exchange: More Restrictive Indications
The threshold for plasma exchange has been raised significantly:
- 2016 EULAR 2: Recommended for serum creatinine ≥500 µmol/L (5.7 mg/dL)
- 2024 KDIGO 1: Consider for SCr >3.4 mg/dL (>300 µmol/L), dialysis-requiring patients, or rapidly increasing SCr
The newer guidelines reflect PEXIVAS trial data showing no mortality or ESKD benefit from routine plasma exchange, making its use more selective rather than standard practice for severe renal involvement.
4. Maintenance Therapy Duration: Extended and Risk-Stratified
2016 EULAR 2: Minimum 24 months after remission induction
2024 KDIGO 1: 18 months to 4 years based on relapse risk factors:
- High-risk features: PR3-ANCA positivity, persistent ANCA positivity, upper respiratory tract involvement, prior relapse
- Extended protocols: Azathioprine can be continued up to 4 years with dose reduction after 18-24 months (1.5-2 mg/kg/d initially, then 1 mg/kg/d)
This represents a more nuanced, individualized approach absent from older guidelines.
5. Rituximab Positioning: From Alternative to Preferred
While both guidelines endorse rituximab, the 2024 KDIGO guidelines 1 provide more explicit guidance:
- Severe renal disease (SCr >4 mg/dL): Consider combination of rituximab with 2 pulses of IV cyclophosphamide
- Maintenance after rituximab induction: Most patients should receive maintenance therapy (not just observation)
- Dosing protocols: Two specific regimens detailed (MAINRITSAN vs. RITAZAREM schemes)
The 2016 guidelines 2 positioned rituximab and cyclophosphamide as equal alternatives without this level of algorithmic specificity.
6. Mycophenolate Mofetil: Expanded Role
2024 KDIGO 1: MMF explicitly included for induction therapy (2000-3000 mg/d) and as maintenance alternative
2016 EULAR 2: MMF mentioned only for non-organ-threatening disease with Grade C evidence
This reflects accumulating evidence supporting MMF's efficacy, particularly in resource-limited settings or when rituximab/cyclophosphamide are contraindicated.
Critical Practice Changes
Induction Therapy Algorithm
The 2024 approach is more algorithmic:
- Rituximab preferred for: PR3-ANCA, relapsing disease, childbearing potential, malignancy history
- Cyclophosphamide preferred for: Severe GN (SCr >4 mg/dL), immediately life-threatening disease
- Combination rituximab + cyclophosphamide: For most severe presentations
ANCA Monitoring
Both guidelines agree: Do NOT use ANCA levels to guide treatment changes 2, 1
However, 2024 guidelines 1 add nuance: ANCA persistence/rise may predict relapse and should inform maintenance duration decisions, though not trigger treatment escalation alone.
Common Pitfalls to Avoid
Do not delay treatment for biopsy in ANCA-positive patients with compatible clinical presentation and rapidly progressive disease 1
Do not use traditional high-dose steroid protocols - the reduced PEXIVAS regimen is now standard of care 1
Do not routinely use plasma exchange for all severe renal AAV - reserve for SCr >3.4 mg/dL or dialysis-dependent patients 1
Do not stop maintenance therapy at 18 months in high-risk patients (PR3-ANCA, prior relapse) - extend to 4 years 1
Do not use methotrexate for maintenance if GFR <60 mL/min/1.73 m² 1
Bottom Line
The evolution from 2016 to 2024 represents a shift toward precision medicine: lower steroid burden, complement-targeted therapy, risk-stratified maintenance duration, and more selective use of plasma exchange. These changes prioritize long-term quality of life while maintaining disease control, reflecting maturation from empiric immunosuppression to mechanistically-informed treatment strategies.